Dizziness clomipramine

SSRIs are well tolerated. Adverse effects for compounds in this class include nervousness, tremor, dizziness, headache, insomnia, sexual dysfunction, nausea, and diarrhea. In addition, the tricycHc antidepressant clomipramine (33), which is a potent nonselective serotonin reuptake inhibitor, is approved for treatment of obsessive—compulsive disorder. 

Treatment with imipramine, the most studied TCA, leaves 45% to 70% of patients panic free. Both desipramine and clomipramine have demonstrated effectiveness in PD as well. Despite their efficacy, TCAs are considered second- or third-line pharmacotherapy due to poorer tolerability and toxicity on overdose.48,49 TCAs are associated with a greater rate of discontinuation from treatment than SSRIs.53 PD patients taking TCAs may experience anticholinergic effects, orthostatic hypotension, sweating, sleep disturbances, dizziness, fatigue, sexual dysfunction, and weight gain. Stimulant-like side effects occur in up to 40% of patients.49... 

The adverse effects of moclobemide have been well reported in several studies, mainly comparisons of moclobemide with standard antidepressants. The consensus has been that moclobemide produces fewer anticholinergic effects and less orthostatic hypotension and dizziness than clomipramine or imipramine. The main problems... 

A 23-year-old woman with ulcerative colitis and no previous psychiatric disorders developed emotional lability, euphoria, persecutory delusions, irritability, and increased motor and verbal activity 3 weeks after starting to take betamethasone 4 mg/day. She improved within a few weeks with bromperidol 3 mg/ day. After 10 months she became unable to speak and eat, was mute, depressive, and sorrowful, and responded poorly to questions. There were no neurological signs and betamethasone had been withdrawn 10 months before. She was treated with intravenous clomipramine 25 mg/day and became able to speak. Intravenous clomipramine caused dizziness due to hypotension, and amoxapine 150 mg/day was substituted after 6 days. All of her symptoms improved within 10 days. Risperidone was added for mood lability and mild persecutory ideation. 

BETA-BLOCKERS AMITRIPTYUNE, CLOMIPRAMINE Risk of T levels of beta-blockers with amitriptyline and clomipramine These TCAs inhibit CYP2D6-mediated metabolism of beta-blockers Monitor BP at least weekly until stable. Warn patients to report symptoms of hypotension (light-headedness, dizziness on standing, etc)... 

Occasional Confusion amnesia disinhibition paradoxical excitement depression dizziness witiidrawal symptoms, including convulsions, on abrupt discontinuance (witiidrawal may be especially difficult with alprazolam) rebound insomnia or excitement Rare Hypotension blood dyscrasias jaundice allergic reactions paradoxical rage reactions stuttering with alprazolam BUPROPION, Anxiety agitation insomnia tremor anorexia BUSPIRONE, Dizziness headache nausea paresthesias diarrhea CHLORDIAZEPOXIDE, see Benzodiazepines CHLORPROMAZINE, see Phenothiazines, aliphatic CHLORPROTHIXENE, similar to Phenothiazines CLOMIPRAMINE, see Tricyclic antidepressants CLORAZEPATE, see Benzodiazepines CLOZAPINE... 

However, 3 patients have developed the serotonin syndrome " and one developed agitation and eonfusion following the use of moclobemide and fluoxetine. A fatal case of the serotonin syndrome occurred in a patient who took an overdose of moclobemide, fluoxetine, and clomipramine, and another patient taking moclobemide developed the serotonin syndrome after taking an overdose of fluoxetine. A study suggests that the combination may cause a high rate of adverse effects (insomnia, dizziness, nausea and headache). ... 

A study in 17 healthy subjects who were extensive metabolisers and taking desipramine 50 mg daily found that when they were also given paroxetine 20 mg daily for 10 days the maximum plasma levels of the desipramine rose by 358%, the trough plasma levels rose by 511% and the AUC rose by 421%. An approximately tenfold increase in the maximum plasma levels and the AUC of the paroxetine also occurred. Another stuty found a fivefold decrease in desipramine clearance in extensive metabolisers given paroxetine 20 mg daily. Paroxetine has also been shown to increase the levels of clomipramine, desipramine, imipramine, and trimipramine. This resulted in a variety of adverse effects including dizziness, confusion, sedation and memory impairment. ... 

---